De novo CD5+ diffuse large B-cell lymphoma: Results of a detailed clinicopathological review in 120 patients

Motoko Yamaguchi, Naoya Nakamura, Ritsuro Suzuki, Yoshitoyo Kagami, Masataka Okamoto, Ryo Ichinohasama, Tadashi Yoshino, Junji Suzumiya, Takuhei Murase, Ikuo Miura, Koichi Ohshima, Momoko Nishikori, Jun Ichi Tamaru, Masafumi Taniwaki, Masami Hirano, Yasuo Morishima, Ryuzo Ueda, Hiroshi Shiku, Shigeo Nakamura

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Background: De novo CD5-positive diffuse large B-cell lymphoma (CD5 + DLBCL) is clinicopathologically and genetically distinct from CD5-negative (CD5-) DLBCL and mantle cell lymphoma. The aim of this retrospective study was to clarify the histopathological spectrum and obtain new information on the therapeutic implications of CD5+ DLBCL. Design and Methods: From 1984 to 2002, 120 patients with CD5+ DLBCL were selected from 13 collaborating institutes. We analyzed the relationship between their morphological features and long-term survival. The current series includes 101 patients described in our previous study. Results: Four morphological variants were identified: common (monomorphic) (n=91), giant cell-rich (n=13), polymorphic (n=14), and immunoblastic (n=2). Intravascular or sinusoidal infiltration was seen in 38% of the cases. BCL2 protein expression in CD5 + DLBCL was more frequent than in CD5- DLBCL (p=0.0003). Immunohistochemical analysis in 44 consecutive cases of CD5+ DLBCL revealed that 82% of these cases (36/44) were non-germinal center B-cell type DLBCL. The 5-year overall survival rate of the patients with CD5+ DLBCL was 38% after a median observation time of 81 months. Patients with the common variant showed a better prognosis than those with the other three variants (p=0.011), and this was confirmed on multivariate analysis. Overall, 16 patients (13%) developed central nervous system recurrence. Conclusions: Our study revealed the morphological spectrum of CD5+ DLBCL, found that the incidence of central nervous system recurrence in this form of lymphoma in high, confirmed that CD5+ DLBCL frequently expresses BCL2 protein and showed that it is mainly included in the non-germinal center B-cell type of DLBCL.

Original languageEnglish
Pages (from-to)1195-1202
Number of pages8
JournalHaematologica
Volume93
Issue number8
DOIs
Publication statusPublished - Aug 1 2008

Keywords

  • BCL2
  • CD5
  • Central nervous system
  • Diffuse large B-cell lymphoma
  • Histopathology

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'De novo CD5<sup>+</sup> diffuse large B-cell lymphoma: Results of a detailed clinicopathological review in 120 patients'. Together they form a unique fingerprint.

  • Cite this

    Yamaguchi, M., Nakamura, N., Suzuki, R., Kagami, Y., Okamoto, M., Ichinohasama, R., Yoshino, T., Suzumiya, J., Murase, T., Miura, I., Ohshima, K., Nishikori, M., Tamaru, J. I., Taniwaki, M., Hirano, M., Morishima, Y., Ueda, R., Shiku, H., & Nakamura, S. (2008). De novo CD5+ diffuse large B-cell lymphoma: Results of a detailed clinicopathological review in 120 patients. Haematologica, 93(8), 1195-1202. https://doi.org/10.3324/haematol.12810